GlassScriptPhysician profile
Lawrence A Kline
NPI 1568463669
$2,906.20
in general payments reported to CMS, 2019-2025
23 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $661 · 2021: $227 · 2022: $27.86 · 2023: $17.93 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,149.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $415.45 | 2019-2021 | |
| Amgen INC. | $398.45 | 2019-2021 | |
| Boston Scientific Corporation | $191.91 | 2025 | Watchman Flx, Cds - Mct/Cem Monitoring |
| Sanofi-Aventis U.S. LLC | $188.90 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $177.85 | 2022-2025 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $173.67 | 2019-2021 | |
| Angiodynamics, INC. | $168.24 | 2025 | Auryon Laser System 100-120 Vac |
| Inspire Medical Systems, INC. | $149.99 | 2025 | Inspire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $133.66 | 2020-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $116.20 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $110.88 | 2019-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $110.55 | 2019-2025 | |
| Philips North America LLC | $90.50 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Arbor Pharmaceuticals, INC. | $82.29 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $70.08 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $64.08 | 2025 | Wegovy |
| Pfizer INC. | $56.44 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $51.70 | 2019 | |
| Amarin Pharma, INC. | $45.92 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.61 | 2019-2025 | Jardiance |
| Medtronic, INC. | $23.08 | 2021 | |
| Cvrx, INC. | $22.57 | 2025 | Barostim Neo System |
| Lundbeck LLC | $21.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Kline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.